The UK’s Alcohol and Drug Board (ADB) has issued new guidance on how to diagnose ALD in adults.
According to the guidance, the diagnosis of ALD requires a blood test to be taken from a person with ALD.
The test should be performed within 12 weeks of the onset of symptoms, and the patient should be able to provide their full name and date of birth.
If the blood test is negative, then the patient needs to go for a liver transplant.
These guidelines are based on the fact that the symptoms of alcoholic liver are similar to those of diabetes.
Dr K. R. Datta, who chairs the ADB, told the Times of Australia that the guidance was “designed to be broadly inclusive of all adults with alcohol-related chronic diseases and who are also at risk of developing ALD, regardless of whether they have diabetes”.
The guidelines say that if there are no symptoms, the person should be assessed as having ALD and that if the patient is still in a state of symptoms when the blood-test results are taken, they should be considered to have the disease.
This is based on what the patient says they feel, and not their physical or mental condition.
“We want people to understand that ALD is a disease, and it’s important to be aware of what we can do to reduce the chances of developing the disease,” Dr Datta said.
He said it was important to ensure that those with ALDs were given the best care possible and that they were treated according to their condition.
“We want to make sure that if a person has the disease, they are not left to die without treatment,” he said.
“We don’t want to give up the right to life.
We want them to get well and to have their lives back.”
In December, the ADG issued a warning that alcohol-associated diabetes is a “significant public health risk” in the US.
In Australia, the new guidelines were issued on the same day that the Australian Diabetes Foundation launched a campaign calling for more research into the links between ALDs and the metabolic syndrome.
A spokesperson for the ADF told The Australian that they had been “encouraged by the ADBG guidance and are hopeful that it will help reduce the need for a transplant and support the ongoing medical research into diabetes”.